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Summary
Objective: To examine whether the baseline ratio of a type II collagen breakdown marker to a synthesis marker, or the level of these markers
individually, is associated with the likelihood of knee osteoarthritis (OA) progression between baseline and 18 months.
Methods: Participants were recruited from community sources and had knee OA. Blood was drawn at baseline. Collagen synthesis was mea-
sured by commercial enzyme-linked immunosorbent assay (ELISA) assay that detects c-propeptide of type II procollagen (CPII). Serum
markers of collagenase cleavage of cartilage type II collagen [C2C epitope (COL2-3/4Clong mono) and C1,2C epitope (COL2-3/4Cshort)]
were also assayed. Knee radiographs (semi-ﬂexed with ﬂuoro conﬁrmation) were obtained at baseline and 18 months. OA progression
was examined using worsening of joint space grade and worsening of Kellgren/Lawrence grade. The relationship between baseline serum
markers and subsequent progression was analyzed from logistic regression.
Results: Baseline levels of these markers, considered individually, were not associated with a change in the odds of progression. Belonging to
the low synthesis tertile was associated with a greater likelihood of progression, approaching signiﬁcance (adjusted odds ratio [OR] 1.86, 95%
conﬁdence interval [CI] 0.96, 3.63). A greater C2C:CPII ratio and C1,2C:CPII ratio were each associated with an increase in the odds of joint
space grade progression, which approached signiﬁcance (e.g., adjusted OR of C2C:CPII ratio was 3.15, 95% CI 0.91, 10.85).
Conclusion: While the degradation markers individually, considered as continuous variables, did not predict OA progression, belonging to the
lower synthesis marker tertile and greater degradation/synthesis marker ratios were associated with an elevation in the odds of progression
albeit not achieving signiﬁcance.
ª 2007 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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SocietyIntroduction
Knee osteoarthritis (OA) is commonly associated with pain
and loss of mobility. Approximately 300,000 total knee re-
placement surgeries are performed annually in the USA
for OA that has progressed to advanced stages1. At pres-
ent, there are no disease-modifying agents to slow or stop
OA progression. One important reason for this is the long
duration required to demonstrate disease modiﬁcation in
therapeutic trials relying upon radiographic outcome mea-
sures. Body ﬂuid markers of cartilage and bone metabolism
may provide a means of identifying patients at greater risk
for progression earlier than the time required to reveal radio-
graphic changes and may also offer a way to gauge the
aggressiveness of OA disease.
Articular cartilage loss is the sine qua non of OA, and
many molecular markers under study are constituents of
cartilage, such as aggrecan epitopes, chondroitin sulfate
epitopes, small proteoglycans, and cartilage collagens2,3.
Type II collagen is a major articular cartilage constituent,
representing 90e95% of its total collagen content and
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Received 7 July 2006; revision accepted 21 January 2007.8forming the ﬁbrils that give cartilage its tensile strength. In
the process of collagen ﬁbril formation, which is enhanced
in OA cartilage4, the C-propeptide is removed from the pro-
collagen extracellularly and directly reﬂects the rate of type
II procollagen synthesis (CPII)4. Cleavage of type II colla-
gen by collagenases is also excessive in OA cartilage5. It
yields fragments, such as the C2C epitope (COL2-3/4Clong
mono)6 and C1,2C epitope (COL2-3/4Cshort)5, which
reﬂect degradation. The C2C assay is speciﬁc for type II
collagen, whereas C1,2C detects the cleavage of both
types I and II collagens.
Several markers have been associated with OA presence
and/or severity in cross-sectional studies; some markers
have also been found to predict OA progression in longitu-
dinal studies7e13. Since OA may result from an imbalance in
cartilage synthesis and degradation, marker approaches
that capture both processes may better predict OA progres-
sion. In support of this, Garnero et al.9 found that the com-
bined Z scores of type II collagen degradation and type IIA
collagen synthesis markers predicted progression more
strongly than either marker individually. While combining Z
scores is a powerful approach, the normative data needed
may not be available and may vary between racial and
ethnic groups. Ratios of biomarkers are another way of
examining cartilage degradation and synthesis together.
Our overall aim was to examine the relationship of type II
collagen A and B synthesis and degradation biomarkers
with knee OA progression as part of the overall and ultimate19
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could serve to predict disease progression and thereby
shorten OA disease-modifying trials. The speciﬁc goal of
this study was to examine whether the baseline ratio of
serum markers of type II collagen breakdown (i.e., collage-
nase cleavage products) to type II collagen synthesis [i.e.,
carboxy (c) propeptide], or the level of these markers
individually, was associated with the likelihood of knee OA
progression between baseline and 18 months later.
Methods
SAMPLE
Study participants were recruited from community sour-
ces (through advertising in periodicals targeting elderly per-
sons, neighborhood organizations, letters to members of
the registry of the Beuhler Centre on Aging at Northwestern
University, via medical center referrals) and met the follow-
ing inclusion criteria: deﬁnite osteophyte presence, Kellgren
and Lawrence (K/L) radiographic grade 2 in one or both
knees; and at least some difﬁculty (Likert category) with
two or more items in the Western Ontario and McMaster
University Osteoarthritis Index physical function scale.
Exclusion criteria were: corticosteroid injection within
3 months, avascular necrosis, rheumatoid or other inﬂam-
matory arthritis, periarticular fracture, Paget’s disease, villo-
nodular synovitis, joint infection, ochronosis, neuropathic
arthropathy, acromegaly, hemochromatosis, Wilson’s dis-
ease, osteochondromatosis, gout, pseudogout, osteopetro-
sis, bilateral K/L 4 knee OA, or bilateral total knee
replacement. Those with past unilateral knee replacement
were eligible if they had OA in the non-replaced knee. Insti-
tutional Review Board approval was obtained. All partici-
pants gave informed consent.
MEASUREMENT OF C2C, C12C, AND CPII
Each participant had blood drawn at baseline. Specimens
were centrifuged for 10 min at 3000 revolutions per minute
to separate serum. Serum was then aliquoted into 1-ml cry-
otubes and stored in a 80 freezer until assayed. Enzyme-
linked immunosorbent assay (ELISA) assays for C1,2C and
CPII were from IBEX Technologies, Montreal, Canada. The
principles of the C2C (COL2-3/4Clong mono) assay (for
the cleavage of type II cartilage collagen by collagenases)6,
the C1,2C (COL2-3/4Cshort) assay (similar to the C2C as-
say but also measures cleavage of type I collagen)5, and
the CPII (carboxy (c) propeptide) assay of type II procolla-
gen (which measures the synthesis of this molecule)4
have been previously described, as has the application
and reproducibility for these serum assays6,14,15. ELISA
kits for C1,2C and CPII were obtained from IBEX Technol-
ogies (Montreal, Canada) and the C2C assay6 was used as
described14.
RADIOGRAPHIC ACQUISITION AND ASSESSMENT
OF PROGRESSION
At baseline and at 18 months, radiographs of both knees
were obtained following a protocol specifying knee position,
criteria for beam alignment relative to knee center, and radi-
opaque markers to account for magniﬁcation16. The knee
was ﬂexed until the tibial plateau was horizontal, parallel
to the beam, and perpendicular to the ﬁlm. To control for
rotation, the heel was ﬁxed and the foot was rotated untilthe tibial spines were centered within the femoral notch.
Knee position (i.e., centering of the spines and superimpo-
sition of the anterior and posterior tibial rims) was conﬁrmed
by ﬂuoroscopy before ﬁlms were taken. Foot maps made at
baseline were used to standardize repositioning at 18
months. All radiographs were obtained in the same unit
by two trained technicians.
OA progressionwas examined usingworsening of the joint
space grade and worsening of K/L grade, as established and
widely used radiographic outcome measures for natural
history studies of knee OA. All available state-of-the-art ac-
quisition protocols were designed and developed tomeasure
joint space in the medial tibiofemoral compartment only. In
contrast, joint space grade progression allows assessment
of both medial and lateral compartments. The compartments
were graded separately using the Osteoarthritis Research
Society International (OARSI) atlas-based scales from
Altman et al. (grade 0 joint space¼ nonarrowing, 1¼ possible
narrowing, 2¼deﬁnite narrowing, 3¼ severe narrowing)17.
Joint space grade progression was deﬁned as worsening of
grade of either compartment in one or both knees.
The K/L grade is a global measure incorporating joint
space assessment, bone changes, and joint deformity. It
was important to apply K/L grade both to allow comparison
of these results to other studies and also to describe the
predictive value of these biomarkers in terms of a global
progression measure. The K/L grade provides a global
score incorporating joint space assessment, bone changes,
and deformity of the joint surface: 0¼ normal; 1¼ possible
osteophytes; 2¼ deﬁnite osteophytes and possible joint
space narrowing; 3¼moderate/multiple osteophytes, deﬁ-
nite narrowing, some sclerosis, and possible attrition of joint
surface; and 4¼ large osteophytes, marked narrowing,
severe sclerosis, and deﬁnite attrition. Progression was
deﬁned as a baseline-to-18-month increase (worsening) of
grade in one or both knees. One experience reader
assessed radiographs using an atlas. Reliability for these
assessments was very good (k coefﬁcient, 0.80e0.86).
STATISTICAL ANALYSIS
Knees with a joint space grade of 3 (the most severe nar-
rowing) in either the medial or lateral compartment or with
a K/L grade of 4 at baseline were excluded from analyses,
since they could not progress further. The relationship be-
tween baseline biomarkers (individual markers and marker
ratios) and subsequent OA progression was analyzed
from logistic regression. Participants were divided into bio-
marker tertile groups to speciﬁcally examine the impact of
belonging to high vs low biomarker groups. Effects of ratios
of biomarkers, calculated from individual assay values, on
the odds of progression were investigated as continuous
predictors. Odds ratios (ORs) and associated 95% conﬁ-
dence interval (CI) were calculated for joint space progression
and K/L progression. A 95% CI excluding 1 is statistically
signiﬁcant. Analyses were adjusted for age (continuous),
gender, body mass index (BMI) (continuous), and baseline
disease severity (maximum of K/L grades of the two knees).
Results
SAMPLE CHARACTERISTICS
Two-hundred and two persons (73% women) were stud-
ied. The mean age was 68.8 10.6 (standard deviation,
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higher K/L grade (of the two knees) was 2 in 96 participants,
3 in 75, and 4 in 31. In 137 participants, K/L grade was 2 or
3 in both knees. The remainder of the participants had only
one knee eligible for progression (the other knee was either
K/L< 2, K/L of 4, or had undergone total knee replacement
previously). Eighty-three (41%) participants had joint space
progression between baseline and 18 months based on ra-
diographic assessment of the tibiofemoral compartment.
Mean levels of each type II collagen marker and the marker
ratios in progressor and non-progressor groups are pro-
vided in Table I.
THE PREDICTION OF PROGRESSION
BY INDIVIDUAL MARKERS
We ﬁrst examined each marker as a continuous variable.
Marker level was not associated with any increase in the
magnitude of the OR for progression (e.g., for joint space
grade progression, the OR, adjusted for age, gender, BMI
and disease severity, associated with C2C was 1.003,
95% CI 0.996, 1.011 and the OR associated with CPII
was 1.00, 95% CI 0.997, 1.002). This was the case for
both the degradation and synthesis markers, and for both
approaches to assess progression.
Next, we applied a tertile approach. Upper limits for tertile
1 were for C2C, 40; for C1,2C 93; and for CPII, 166. Tertile
2 upper limits were: for C2C, 63; for C1,2C, 132; and for
CPII, 246. Tertile 3 upper limits were: for C2C, 330; for
C1,2C, 289; and for CPII, 690. For the degradation markers,
the impact of belonging to the higher tertiles (tertile 2 or 3)
(with the lowest tertile as reference) on subsequent pro-
gression was examined. For the synthesis marker, the
impact of belonging to the two lower tertiles (tertile 1 or 2)
(with the highest tertile as reference) on subsequent pro-
gression was examined. Belonging to a low synthesis
tertiles (but not to the high degradation tertiles) was associ-
ated with a greater likelihood of progression that ap-
proached signiﬁcance (see Table II).
PREDICTION OF PROGRESSION BY DEGRADATION/
SYNTHESIS RATIO
There was no correlation between either of the degrada-
tion markers with CPII (i.e., R¼ 0.09 for C2C and 0.12 for
C1,2C). As shown in Table III, the C2C:CPII ratio and
C1,2C:CPII ratio were each associated with an elevation
in the odds of joint space grade progression. Results
were minimally affected by adjusting for age, gender, BMI,
and baseline disease severity. A non-signiﬁcant elevation
in the OR was also seen when progression was examined
as worsening of K/L grade. Analyses were repeated in a
homogeneous subset of persons with K/L 2 or 3 in both
knees (n¼ 137). Results were very similar, revealing norelationship between markers examined individually, and
an elevation in OR for progression associated with degrada-
tion to synthesis marker ratio (i.e., OR 2.76 for C2C:CPII).
Discussion
This study examined whether the ratio of serum markers
of type II collagen breakdown (i.e., collagenase cleavage
[C2C; C1,2C]) to type II collagen synthesis (i.e., carboxy
(c) propetide [CPII]), and these markers individually, at
baseline were associated with the likelihood of knee OA
progression between baseline and 18 months. There was
no relationship between marker level and progression
when the markers were examined individually as continu-
ous variables. Belonging to the lower synthesis (i.e., CPII)
tertile was associated with an increase in the odds of pro-
gression that approached signiﬁcance. The ratios were as-
sociated with an increase in the likelihood of progression in
the next 18 months that approached signiﬁcance, especially
the C2C:CPII ratio for joint space grade progression.
The CPII tertile results introduce the possibility that this
synthesis marker may have some predictive value but that
its relationship with progression may be non-linear. Future
studies should examine potential cut-offs for what consti-
tutes high and low levels of CPII. Previous studies of CPII
(which detects both type IIA and B collagens4) and the
N-propeptide of type IIA collagen (which only detects the
minor type IIA collagen18) have revealed that they are de-
creased in patients with knee OA. We were not able to iden-
tify a previous study applying a quantile approach for
a synthesis marker. Previously, Reijman et al.10 found
that persons in the highest quartile of urinary concentration
of C-telopeptide, the type IIA and B non-helical degradation
marker, had a six-fold increased risk for progression of
radiographic knee OA examined over a 6-year follow-up.
Table II
OR for joint space grade progression associated with marker tertile
Marker tertile OR (95% CI) Age, gender, BMI,
disease severity,
adjusted OR (95% CI)
C2C tertile 2 or 3
(reference tertile 1)
0.81 (0.45, 1.47) 0.90 (0.49, 1.67)
C1,2C tertile 2 or 3
(reference tertile 1)
0.73 (0.40, 1.32) 0.78 (0.42, 1.43)
CPII tertile 1 or 2
(reference tertile 3)
1.85 (0.99, 3.46) 1.86 (0.96, 3.63)
The OR for joint space grade progression associated with be-
longing to the given marker tertile is shown with the 95% CI ﬁrst un-
adjusted then adjusted for age, gender, BMI, and baseline disease
severity. A 95% CI excluding 1 is signiﬁcant.Table I
Sample mean of type II collagen markers. Mean and SD of each marker and marker ratio are shown for the full sample (n¼ 202), progressors
(n¼ 83), and non-progressors (n¼ 119)
Type II collagen marker MeanSD (full sample) MeanSD in progressors MeanSD in non-progressors
C2C epitope
(degradation marker)
59 41 pmol/ml 63 53 pmol/ml 57 30 pmol/ml
C1,2C epitope
(degradation marker)
119 56 pmol/ml 118 57 pmol/ml 120 55 pmol/ml
CPII (synthesis marker) 223 108 ng/ml 217 121 ng/ml 227 99 ng/ml
C2C:CPII ratio 0.31 0.24 0.35 0.30 0.29 0.19
C1,2C:CPII ratio 0.64 0.41 0.69 0.48 0.60 0.35
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ORs for knee OA progression associated with marker ratio (n¼ 202)
Marker ratio Joint space grade progression K/L grade progression
OR (95% CI) Adjusted*
OR (95% CI)
OR (95% CI) Adjusted*
OR (95% CI)
C2C:CPII ratio 2.82 (0.86, 9.25) 3.15 (0.91, 10.85) 1.98 (0.62, 6.35) 2.18 (0.65, 7.3)
C1,2C:CPII ratio 1.68 (0.84, 3.38) 1.79 (0.87, 3.69) 1.70 (0.84, 3.46) 1.79 (0.86, 3.72)
The table shows the OR for joint space grade progression and for K/L grade progression per unit change in marker ratio, ﬁrst unadjusted and
then adjusted for age, gender, BMI, and baseline disease severity.
*Adjusted for age, gender, BMI, and baseline disease severity. A 95% CI excluding 1 is signiﬁcant.Our results suggest that biomarkers of type II collagen
synthesis may be more informative than measuring intrahel-
ical type II collagen degradation alone. This result is in
keeping with the concept that pro-inﬂammatory cytokines,
which, at low levels, are more effective in suppressing
collagen synthesis than promoting collagen degradation19,
may play a role in loss of homeostasis reﬂected by OA
progression.
The current ﬁndings for the ratios are in keeping with the
concept that a failure of cartilage synthesis to keep pace
with degradation may be associated with OA progression.
This observation is of interest since it is known that degen-
erate articular cartilage in OA is characterized by an appar-
ent imbalance in matrix catabolism and anabolism20. For
example, there is increased cleavage of type II collagen
by collagenases5,21 and increased synthesis of type II pro-
collagen4. Newly synthesized collagen is also rapidly de-
graded favoring catabolism21. But, serum analyses have
revealed a reduction in biomarkers of synthesis of type II
collagen associated with a greater likelihood of progression
of knee OA4,9,18. Synthetic differences measured in serum
may reﬂect genetically determined systemic differences in
hyaline cartilage metabolism that in turn may inﬂuence dis-
ease onset and progression rather than reﬂecting pathology
within the joint.
Two other longitudinal studies have examined the predic-
tive value of concomitant consideration of synthesis and
degradation markers. Garnero et al.9 calculated an uncou-
pling index, using the Z scores of serum N-propeptide of
Type IIA procollagen (PIIANP), a synthesis marker, and
urinary C-terminal crosslinking telopeptide of Type II colla-
gen (CTX-II), a degradation marker. A greater uncoupling
index at baseline was associated with greater knee OA
progression, evaluated either by joint space narrowing
(R¼ 0.46) or by direct visualization arthroscopically
(R¼ 0.36). Furthermore, patients with both low baseline
levels of PIIANP and high baseline levels of CTX-II had
an eight-fold increase in the likelihood of progression, sug-
gesting that considering both degradation and synthesis
may better at identifying persons most likely to progress
(than markers considered individually). In another recent
study in which progression was assessed over 30 months
using medial tibiofemoral joint space narrowing22, the
C2C/CPII ratio was associated with an elevated but non-
signiﬁcant OR of 1.67 (95% CI 0.87, 3.14) in the 60 persons
receiving doxycycline but not in the placebo group (also
numbering 60) (OR 0.82, 95% CI 0.50, 1.45). The reason
for this difference is unclear.
The present observations have interesting parallels for
the same biomarkers when they have been used to study
the progression of naturally occurring OA in the knee joints
of guinea pigs23. The Hartley strain develops more exten-
sive knee OA than strain 13 over a period of 1 year. Com-
pared to strain 13, this is also accompanied at 12 months bya reduction in the same serum CPII type II collagen biosyn-
thesis marker and an increase in the serum C2C degrada-
tion marker in the Hartley strain. The ratio of C2C/CPII is
also increased in Hartley guinea pigs as are a number of
pro-inﬂammatory cytokines and chemokines23.
Other predictive serum markers for progression which
have been identiﬁed in longitudinal human studies include
hyaluronic acid (hyaluronan)7,12, C-reactive protein11, stro-
meylsin-1 (MMP-3)13 and cartilage oligomeric matrix pro-
tein8,24,25. Changes in molecular markers over time may
also have better predictive value for progression than
marker levels from one time-point. Bruyere et al.26 found
that a 1-year increase in serum osteocalcin or a 1-year de-
crease in serum hyaluronic acid from baseline predicted
progression at 3 years.
It is important to acknowledge that the results for the ratio
of C2C to CPII in our study approached but did not achieve
signiﬁcance. We believe there are important reasons to re-
port on these results. First, the OR for progression associ-
ated with the degradation to synthesis marker ratio was
consistently elevated (deleterious effect), and may have
achieved signiﬁcance in a larger sample. In contrast, the
OR for progression appeared to be unrelated to the levels
of individual markers. Second, the longitudinal studies in
the literature appear to describe somewhat striking results
in one or only a few cohorts for each marker, introducing
a concern that there may be underreporting of negative or
less impressive results.
Our ﬁndings for the measurement of total type II collagen
turnover are less impressive than those of Garnero et al.9
This difference may not only be related to the different
markers themselves but rather to how the markers were
combined; combining Z scores may be a superior approach.
Moreover, in this previous study, only 16 progressors and
36 non-progressors were examined over 1 year. Clearly, fu-
ture appropriately powered studies should include head to
head comparisons of these different markers and their com-
binations using the same methodologic approach to assess
progression.
There are limitations to our study that may help to explain
the relative weakness of the ﬁndings. We used radiographic
measures of progression; quantitative assessment of carti-
lage volume by MRI may be a superior means of demon-
strating the predictive value of these biomarkers. Also we
did not adjust for total body burden of OA, which undoubt-
edly complicates the serum assessment of cartilage
biomarkers.
In summary, the ratio of a marker reﬂecting type II colla-
gen degradation (C2C) to a type II procollagen synthesis
marker (CPII) was more closely related to knee OA progres-
sion over the next 18 months, than these markers examined
separately. Future studies should consider ratio ap-
proaches and other methods of combining markers in an
effort to identify synthesis and degradation combinations
823Osteoarthritis and Cartilage Vol. 15, No. 7to more powerfully (than the current study approach) predict
progression.
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